Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCLA-129 and Ensartinib in advanced solid tumors
NCT07448116Phase 2Recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- Jan 2026
- Primary completion
- Feb 2029
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pamvatamig in solid tumor, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Betta Pharmaceuticals. Started Jan 2026; status: recruiting.
02
Drugs
pamvatamig
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07448116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07448116.